Is the price fair?
What BNTX's price assumes
BioNTech SE did not earn a profit over the last twelve months, so it has no trailing P/E and the price is read against sales instead: 0.86× revenue.
0.86
Price / sales · no P/E: the last twelve months did not end in a profit
- Price / book
- 1.20
Price / book · as of 2025-FY
Details›
- Price / book2025-FY
- 1.20
- EV / EBIToperating margin −49%: the multiple describes the denominator
- not meaningful
- Market capitalisation
- $23.0B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Biotechnology
Ranks #105 of 145 by Smart Score